The Amyloid/Tau/Neurodegeneration (ATN) framework, proposed by the National Institute on Aging and Alzheimer’s Association in 201810, is considered the gold standard for diagnosing Alzheimer’s disease. This evidence concerns the gene MAPT and Alzheimer disease.